Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference

by Walter Gunzburg | Sep 26, 2026 | Press Release

This press release can be viewed online at: https://ir.avaibio.com/press-releases/2026/avai-bio-and-austrianova-present-encapsulated-cell-approach-to-sustained-klotho-delivery-at-2026-klotho-conference Watch Austrianova Founder & CTO, Prof. Walter Gunzburg...

Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes

by Walter Gunzburg | Aug 13, 2026 | Press Release

This press release can be viewed online at: https://www.globenewswire.com/news-release/2026/08/12/3343647https://www.einpresswire.com/article/634030792/ Agreement combines Austrianova’s Cell-in-a-Box® technology with San Raffaele Hospital’s stem cell-derived beta cell...

Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy

by Walter Gunzburg | May 21, 2026 | News

LAS VEGAS, May 20, 2026 /PRNewswire/ — Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today...

SG Austria/Austrianova Announces the Appointment of C. Thomas Paschall, to the Board following the Successful closing of 2025 Financing Round Led by Checkmate Capital Group

by Walter Gunzburg | Apr 23, 2026 | News

“SG Austria/Austrianova appoints biotech investor C. Thomas Paschall to its Board following a successful 2025 funding round, strengthening global growth, partnerships, and strategic expansion initiatives.”   SINGAPORE – April 21, 2026 – SG...

Avant Technologies and Austrianova Secure Exclusive License for Klotho Producing Cell Line to Advance Anti-Aging Therapies

by Walter Gunzburg | Nov 19, 2025 | News, Press Release

LAS VEGAS, NEVADA, November 18, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced that its 50/50 joint venture...